Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

Last updated:
2026-08-15
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WITH PERIPHERAL ARTERY DISEASE: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

Intervention/treatment:
ORFORGLIPRON (LY3502970)
Medical condition:
PERIPHERAL ARTERY DISEASE
Protocol code:
J2A-MC-GZPR
Control number:
301509
Status:
Recruiting
Approved:
October 02, 2025
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT07223593
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Role
CONTACT
Phone:
317-615-4559
Name
Physicians interested in becoming principal investigators please contact
Role
CONTACT
Sponsor
ELI LILLY CANADA INC

Locations

Alpha Recherche Clinique - Lévis
Lévis, G6V 0C9
RECRUITING
Role
CONTACT
Phone:
418-380-1112
Name
Steeve Kwan Tat
Role
PRINCIPAL_INVESTIGATOR
Cardio 1 Medical Clinic
Winnipeg, R3L 1Z5
RECRUITING
Role
CONTACT
Phone:
204-287-5222 ext 104
Name
Peiman Malek Marzban
Role
PRINCIPAL_INVESTIGATOR
Corcare
Toronto, M1B 5N1
RECRUITING
Role
CONTACT
Phone:
416-284-4744
Name
Paul Galiwango
Role
PRINCIPAL_INVESTIGATOR
KMH Cardiology Centres - Stoney Creek
Stoney Creek, L8J 3W2
RECRUITING
Role
CONTACT
Phone:
905 855 1860
Name
Fatima Merali
Role
PRINCIPAL_INVESTIGATOR
THEO Medical Concorde
Laval, H7G 2E6
RECRUITING
Role
CONTACT
Phone:
438-320-7171
Name
Mohamed Medhi Khider
Role
PRINCIPAL_INVESTIGATOR
Toronto General Hospital
Toronto, M5G 2C4
NOT_YET_RECRUITING
Name
Thomas Lindsay
Role
PRINCIPAL_INVESTIGATOR
Unity Health Toronto, St. Michael's Hospital
Toronto, M5B 1W8
NOT_YET_RECRUITING
Name
Beth Abramson
Role
PRINCIPAL_INVESTIGATOR
Did you find what you were looking for?